Miguel A. de los Ríos
Fondateur chez Endeavor BioMedicines, Inc
Profil
Miguel A.
de los Ríos was the founder of Chimeros, Inc. (founded in 2003) where he held the titles of Chairman, CEO & Chief Scientific Officer from 2009 to 2011, and RIFT biotherapeutics, Inc. (founded in 2015) where he held the title of Director, Chief Executive & Engineering Officer.
Dr. de los Ríos is also the founder of Endeavor BioMedicines, Inc. He held former positions as Vice President-Research at Sevion Therapeutics, Inc. from 2014 to 2015, Principal at Chimeros Therapeutics from 2000 to 2012, and Vice President-Research & Development at Fabrus, Inc. Dr. de los Ríos received his doctorate degree from the University of California, Santa Barbara in 2005.
Postes actifs de Miguel A. de los Ríos
| Sociétés | Poste | Début |
|---|---|---|
Endeavor BioMedicines, Inc
 Endeavor BioMedicines, Inc Miscellaneous Commercial ServicesCommercial Services Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation. | Fondateur | - |
Anciens postes connus de Miguel A. de los Ríos
| Sociétés | Poste | Fin |
|---|---|---|
Chimeros Therapeutics
 Chimeros Therapeutics Medical SpecialtiesHealth Technology Chimeros Therapeutics develops cancer therapeutic treatment services. The company is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Chimeros, Inc.
 Chimeros, Inc. Pharmaceuticals: MajorHealth Technology Chimeros, Inc. develops novel therapies for cancer treatment. It focuses on the development of novel targeted treatments while generating immediate revenues from licensing platform rights and development contracts. Chimeros was founded in 2004 and is headquartered in San Diego, CA. | Directeur Général | 01/01/2011 |
RIFT biotherapeutics, Inc.
 RIFT biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services RIFT biotherapeutics, Inc. operates as a therapeutic antibody company that focuses on immuno-oncology targets outside of the T-cell space. It generates therapeutic antibodies that harness the immune system, to target cancers in areas of unmet needs. The company was founded by Miguel A. de los Ríos, Cornelia Bentley, and Jeff Pitman in 2015 and is headquartered in San Diego, CA. | Directeur Général | - |
Fabrus, Inc.
 Fabrus, Inc. BiotechnologyHealth Technology Fabrus, Inc. engages in discovering, developing and engineering therapeutic antibodies. It utilizes multiple proprietary product engines that define a new antibody discovery paradigm. The company is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | - |
Sevion Therapeutics, Inc.
 Sevion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sevion Therapeutics, Inc. operates as Biopharmaceutical Company. It discovers, develops and acquires product candidates for the treatment of cancer and immunological diseases. The company was founded on September 30, 1999 and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | - |
Formation de Miguel A. de los Ríos
| University of California, Santa Barbara | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Chimeros, Inc.
Chimeros, Inc. Pharmaceuticals: MajorHealth Technology Chimeros, Inc. develops novel therapies for cancer treatment. It focuses on the development of novel targeted treatments while generating immediate revenues from licensing platform rights and development contracts. Chimeros was founded in 2004 and is headquartered in San Diego, CA. | Health Technology |
Chimeros Therapeutics
Chimeros Therapeutics Medical SpecialtiesHealth Technology Chimeros Therapeutics develops cancer therapeutic treatment services. The company is headquartered in San Diego, CA. | Health Technology |
Sevion Therapeutics, Inc.
Sevion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sevion Therapeutics, Inc. operates as Biopharmaceutical Company. It discovers, develops and acquires product candidates for the treatment of cancer and immunological diseases. The company was founded on September 30, 1999 and is headquartered in San Diego, CA. | Commercial Services |
Fabrus, Inc.
Fabrus, Inc. BiotechnologyHealth Technology Fabrus, Inc. engages in discovering, developing and engineering therapeutic antibodies. It utilizes multiple proprietary product engines that define a new antibody discovery paradigm. The company is headquartered in San Diego, CA. | Health Technology |
RIFT biotherapeutics, Inc.
RIFT biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services RIFT biotherapeutics, Inc. operates as a therapeutic antibody company that focuses on immuno-oncology targets outside of the T-cell space. It generates therapeutic antibodies that harness the immune system, to target cancers in areas of unmet needs. The company was founded by Miguel A. de los Ríos, Cornelia Bentley, and Jeff Pitman in 2015 and is headquartered in San Diego, CA. | Commercial Services |
Endeavor BioMedicines, Inc
Endeavor BioMedicines, Inc Miscellaneous Commercial ServicesCommercial Services Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation. | Commercial Services |
